Currently, the conventional therapeutic options for IBD including immunomodulators, thiopurine agents, anti-TNF-α monoclonal antibodies are still not satisfactory due to their undesirable side effects [40]. The gene discussed is TNF; the disease is inflammatory bowel disease.